Dexamethasone sodium phosphate injection is indicated to treat various conditions such as endocrine disorders, arthritis, blood disorders, dermatologic diseases, severe allergic reactions, eye diseases, certain cancers, gastrointestinal diseases and respiratory diseases.
Akorn-Strides is a joint venture formed in 2005 by Akorn and Strides Arcolab. The primary mission of the joint venture is to develop liquid, lyophilized and dry powder formulations of generic injectable products targeting several therapeutic markets with a major focus on anti-infectives, analgesics and CNS medicines.
Arthur Przybyl, president and CEO of Akorn and member manager of Akorn-Strides, said: “We are excited to announce these two ANDA product approvals for dexamethasone sodium phosphate injection.”